Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Distriphil
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 26, 2020
Details:
Luye Pharma grants Distriphil the exclusive distribution and marketing rights for the central nervous system drugs Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in the Philippines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CAP ALTER PHARMA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 11, 2020
Details:
Luye Pharma granted exclusive promotional rights to CAP ALTER PHARMA, INC (Alter-Pharma) for Seroquel products in 9 countries and regions including Costa Rica, Jamaica, Trinidad and Tobago, Barbados, Aruba, Curacao, Bahamas, Bermuda and The Cayman Islands.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Alvogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 01, 2020
Details:
Luye Pharma granted Alvogen Korea, Zuellig Pharma and DKSH exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hong Kong and Thailand.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Moksha8
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 14, 2020
Details:
Moksha8 subsideries, Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda and Moksha8 Farmacéutica, S. de R.L. de C.V have been granted the exclusive promotion rights for the two central nervous system (CNS) drugs: Seroquel® and Seroquel XR® in Brazil and Mexico.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cipla Medpro
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2020
Details:
Luye Pharma granted the distribution and marketing rights to Cipla Medpro in South Africa and neighbouring countries on the basis of its robust business network and resources in local markets.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
